Commonwealth Equity Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.07M Sell
291,939
-29,052
-9% -$96.7K ﹤0.01% 2670
2026
Q1
$985K Buy
320,991
+235,648
+276% +$911K ﹤0.01% 2631
2025
Q4
$349K Buy
85,343
+39,303
+85% +$195K ﹤0.01% 3523
2025
Q3
$225K Sell
46,040
-13,581
-23% -$71.3K ﹤0.01% 3866
2025
Q2
$302K Sell
59,621
-6,722
-10% -$33K ﹤0.01% 3574
2025
Q1
$351K Buy
66,343
+12,024
+22% +$87.7K ﹤0.01% 3350
2024
Q4
$367K Sell
54,319
-4,582
-8% -$30.8K ﹤0.01% 3231
2024
Q3
$388K Buy
58,901
+14,660
+33% +$105K ﹤0.01% 3115
2024
Q2
$332K Buy
44,241
+9,058
+26% +$79K ﹤0.01% 3212
2024
Q1
$351K Buy
35,183
+13,183
+60% +$147K ﹤0.01% 3131
2023
Q4
$217K Buy
22,000
+815
+4% +$5.81K ﹤0.01% 3445
2023
Q3
$162K Buy
21,185
+5,550
+35% +$55.4K ﹤0.01% 3460
2023
Q2
$117K Buy
+15,635
New +$109K ﹤0.01% 3547

Other funds holding RXRX

Commonwealth Equity Services's RXRX Position: Q2 2026 in Review

Commonwealth Equity Services reduced its Recursion Pharmaceuticals (RXRX) stake by 9.1% in Q2 2026, selling an estimated $96.7K and leaving 291,939 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2670.

Commonwealth Equity Services first reported a position in RXRX in Q2 2023 and has held it in 13 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Commonwealth Equity Services held 291,939 shares of Recursion Pharmaceuticals worth $1.07M as of Q2 2026.
  • Commonwealth Equity Services sold 29,052 Recursion Pharmaceuticals shares in Q2 2026, an estimated $96.7K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #2670 holding.
  • Commonwealth Equity Services first reported a position in Recursion Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.